There is one clinical trial.
Currently there is no known effective therapy or vaccine for treatment of SARS-CoV-2, highlighting urgency around identifying effective therapies. This study aiming to evaluate the anti-HCV medications efficacy "Sofosbuvir-Ledipasvir" in treatment of moderate cases with SARS-COV-2 infection, in comparison to the standard treatment (hydroxychloroquine, oseltamivir and azithromycin).
Description: Cured: Documented virological clearance in 2 samples at least 24 hours apart.Measure: Therapeutic success (cured) Time: 21 days
Description: any incidence of deaths for any participant within 28 days from starting the treatmentsMeasure: 28 days in hospital mortality Time: 28 days
Description: participants who failed to achieve documented virological clearance in 2 samples at least 24 hours apart.Measure: Percentage of clinical failure of treatments Time: 21 Days
Description: days of length of hospital staying in isolation till documented virological clearance in 2 samples at least 24 hours apart.Measure: Length of hospital stay Time: Through study completion, an average of 14 weeks
Description: Incidence of any side effects known to be related to the medication administrated either in group 1 or 2Measure: Incidence of side effects Time: 21 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports